Memorial Sloan Kettering Cancer Center

United States

Memorial Sloan Kettering Cancer Center

United States
SEARCH FILTERS
Time filter
Source Type

News Article | April 28, 2017
Site: news.yahoo.com

(Reuters Health) - Having a family history of prostate cancer doesn’t make it more risky for men with a new diagnosis of the disease to initially hold off on active treatment in favor of monitoring with periodic lab tests, a research review suggests. It’s becoming more common for doctors to skip aggressive treatments like surgery or radiation for men with low-risk prostate tumors in favor of doing periodic tests to see if tumors grow, a practice known as active surveillance. But research to date has offered a mixed verdict on whether this approach is safe for certain men with a higher risk, including black patients and people with a family history of prostate tumors. For the current study, researchers analyzed data from six previously published studies and found that active surveillance wasn’t linked with an increased risk of prostate cancer progressing for men with a family history. One study did, however, find that family history increased the risk of cancer progression in black men. “The current findings can help doctors reassure patients that having a family history of prostate cancer should not automatically exclude them from being considered for active surveillance, although more research needs to be done for African American men,” said senior study author Dr. James Dupree, a urology researcher at the University of Michigan in Ann Arbor. Most men with prostate cancer are diagnosed with low-risk tumors that haven’t spread to other parts of the body. Often, doctors and patients struggle to choose the best course of action because it's hard to tell which tumors will grow fast enough to be life-threatening and which ones might never get big enough to cause problems. “Just because a cancer is found, it does not automatically mean it needs to get treated right away,” Dupree said by email. “In some cases, cancer should be treated, but in other cases it may not need immediate treatment and can be managed with active surveillance.” For example, Dupree and colleagues reviewed one study of 200 patients that didn’t detect a meaningful difference in high-risk tumors based on whether or not men had a family history. In men who did have a family history, this study also didn’t find a difference in risk based on the number of relatives with prostate cancer. Two other studies in the review looked at biomarkers for prostate tumors, including results from prostate specific antigen (PSA) tests that are commonly used to look for these malignancies. Neither study found family history to be a meaningful predictor of aggressive prostate cancer. In another study, family history wasn’t a good predictor of aggressive tumors for most men, but it did signal an increased risk for black men. One limitation of the research review is that it included only six studies, the authors note in BJU International. Still, the findings should reassure men with a family history of prostate cancer that active surveillance may be a reasonable option in some cases, said Dr. Behfar Ehdaie, a urologic surgeon at Memorial Sloan Kettering Cancer Center in New York who wasn’t involved in the study. “Screening for prostate cancer saves lives,” Ehdaie said by email. “However, the decisions after prostate cancer is detected may lead to overtreatment.” To strike the right balance, doctors can screen men at a young age with a PSA blood test to help determine a patient’s future risk, then recommend an appropriate treatment after a man is diagnosed with prostate cancer, Ehdaie added. “Incorporating active surveillance to treat men with low risk prostate cancer reduces the harms of overtreatment associated with both surgery and radiation therapy,” Ehdaie said.


News Article | May 4, 2017
Site: www.businesswire.com

SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the first quarter 2017. “ In the first quarter 2017, we made significant progress with our lead program, JCAR017, and we look forward to presenting updated data in DLBCL at ASCO," said Hans Bishop, Juno’s President and Chief Executive Officer. " We also continue to advance our pipeline more broadly with eleven product candidates now in human testing. Already this year, we have initiated a number of trials, including a BCMA CAR T, a CD19-directed 4-1BBL armored CAR, a fully-human CD19 CAR T, a combination trial with JCAR014 and durvalumab, and a combination trial with JCAR014 and ibrutinib. With up to 20 ongoing trials by year end, we expect to gain additional insights that may lead to product candidates that can deliver long-term durable remissions for patients in need.” A reconciliation of GAAP net loss to non-GAAP net loss and GAAP R&D expense to non-GAAP R&D expense is presented below under “Non-GAAP Financial Measures.” Juno reaffirms 2017 cash burn, excluding cash inflows or outflows from upfront payments related to business development activities, of between $270 million and $300 million. Juno will host a conference call today to review Juno’s financial results for the first quarter 2017 beginning at 2:00 p.m. Pacific Time (PT)/5:00 p.m. Eastern Time (ET). Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 7603931. The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call. Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno's product candidate JCAR017 was developed in collaboration with SCRI and others. Celgene Corporation and Juno Therapeutics formed a collaboration in June 2015 under which the two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. In April 2016, Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans; clinical trial plans and timelines; planned data presentations; the potential of combinations of CAR T cells with checkpoint inhibitors, armored CARs, and CAR T constructs with fully human binding domains; the potential of the Celgene collaboration; the potential of Juno's clinical trials to generate insights that lead to product candidates that deliver long-term durable remissions; and 2017 cash burn forecast. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements. To supplement the financial results presented in accordance with generally accepted accounting principles in the United States (GAAP), Juno uses certain non-GAAP financial measures to evaluate its business. Juno’s management believes that these non-GAAP financial measures are helpful in understanding Juno’s financial performance and potential future results. These are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Juno’s financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting. Juno’s management uses these supplemental non-GAAP financial measures internally to understand, manage, and evaluate Juno’s business and make operating decisions. In addition, Juno’s management believes that the presentation of these non-GAAP financial measures is useful to investors because they enhance the ability of investors to compare Juno’s results from period to period and allows for greater transparency with respect to key financial metrics Juno uses in making operating decisions. Juno endeavors to compensate for the limitation of the non-GAAP measures presented by also providing the most directly comparable GAAP measures and descriptions of the reconciling items and adjustments to derive the non-GAAP measures. The following is a reconciliation of GAAP to non-GAAP financial measures: (1) The success payment expense (gain) represents the change in the estimated fair value of the success payment obligations and the associated elapsed service period. As of March 31, 2017, the estimated fair values of the success payment liabilities to FHCRC and MSK on the condensed consolidated balance sheets, were approximately $17.7 million and $12.5 million, respectively. If success payment thresholds are met in the future, Juno may pay FHCRC and MSK the applicable success payment in cash or publicly-traded equity at Juno’s election. The success payment liabilities are subject to re-measurement each reporting period and may fluctuate from quarter-to-quarter and year-to-year, sometimes significantly, resulting in either an expense or a gain depending on the trading price of Juno common stock, estimated term, expected volatility, risk-free interest rate, estimated number and timing of valuation measurement dates, and estimated indirect costs that are creditable against the success payments to FHCRC and MSK. (2) This relates to a restricted stock grant in 2013 to a former co-founding director who became a consultant upon his departure from Juno’s board of directors in 2014. Unlike other outstanding awards to Juno’s employees, scientific founders, and continuing directors, the value of this restricted stock award is subject to re-measurement each reporting period as the award vests and may result in the associated expense fluctuating from quarter-to-quarter and year-to-year, sometimes significantly, based on changes in the trading price of Juno common stock through the end of the vesting period. (3) This is the change in the estimated fair value of the contingent consideration liabilities recorded in connection with the Stage and X-Body acquisitions.


Techonomy Returns to New York for Two Days of Intense Conversation About Technology’s Impact on Business and Society Techonomy, a leading events and media company focused on helping organizations and executives prepare for the rapid pace of tech-enabled transformation, will hold two consecutive events, Techonomy Health & Techonomy NYC, in New York City on May 16th & 17th. Techonomy, a leading events and media company focused on helping organizations and executives prepare for the rapid pace of tech-enabled transformation, will hold two consecutive events, Techonomy Health & Techonomy NYC, in New York City on May 16th & 17th. “We love our home city in New York and we love helping leaders engage with ideas about tech-driven change, so we are especially proud to be doing that here for the second year in a row,” said David Kirkpatrick, CEO and Chief Techonomist and author of the bestselling book, The Facebook Effect: The Inside Story of the Company that is Connecting the World. "We're inviting techonomic thinkers to join us for either one or both of two days – Techonomy Health first, and then Techonomy NYC on May 17." Techonomy Health explores the vast potential tech holds to remake this $3 trillion U.S. industry. The program includes healthcare experts, technologists, policy makers and entrepreneurs for a high-energy discussion around topics including how AI and CRISPR will change the war on cancer, the future of consumer health information and media, the ethical and moral quandaries of enhancing the human genome, and what Trumpcare and Obamacare mean for health innovation. Speakers include Len Greer, President, Johnson & Johnson Health and Wellness; Meredith Guerriero, director for the healthcare industry at Facebook; Arianna Huffington, Founder and CEO, Thrive Global; John Mattison, Chief Medical Information Officer, Kaiser Permanente; celebrated author and holistic medicine expert Dean Ornish; Claudia González Romo, Executive Office of the Secretary General, UNICEF; Oscar CEO Mario Schlosser; Brent Shafer, CEO of Philips North America; and Steven Zatz, CEO of WebMD. (Full list below.) The following day, Techonomy NYC will be a New York-style version of Techonomy’s longstanding retreat in California, where last fall Mark Zuckerberg famously spoke about fake news. Techonomy NYC will ignite invigorating discourse around ongoing challenges relating to what a government led by Trump means for technology; the future of work in an on-demand gig economy; the digital and social fight against terrorism; and tough-to-answer questions about decision making power in an AI world, among many other topics. Speakers include Beth Comstock, Vice Chair of GE; Karin Klein, Head of Investing Activities at VC firm Bloomberg Beta; Environmental Defense Fund President Fred Krupp; Turner CEO John Martin; Miguel McKelvey, Co-founder and Chief Creative Officer of WeWork; Eli Pariser, Co-founder and Co-CEO of Upworthy; and General Assembly CEO Jake Schwartz. (Full list below.) Techonomy's partners for the conferences include Accenture, Celestica, Cognizant, Johnson & Johnson, Paypal, Philips, Pitney-Bowes, and Turner Broadcasting. Techonomy Health confirmed speakers include: Yonatan Adiri, Founder and CEO, Healthy.io and Founder, DisruptionLabs; Agnes Binagwaho Vice Chancellor, University of Global Health Equity; Jef Boeke, Director of the Institute for Systems Genetics, NYU Langone Medical Center; Walter De Brouwer, Founder and CEO, doc.ai; Brian Donley, Chief of Staff, Cleveland Clinic; David Ewing Duncan, Co-Founder, Curator and CEO, Arc Fusion; Esther Dyson, Chairman, EDventure Holdings; Katelyn Gleason, CEO & Cofounder, Eligible; Claudia González Romo, Executive Office of the Secretary General, UNICEF; Len Greer, President, Johnson & Johnson Health and Wellness Solutions; Meredith Guerriero, director for the healthcare industry at Facebook Ron Gutman, Founder and CEO, HealthTap; Jill Hagenkord, Chief Medical Officer, Color Genomics; Arianna Huffington, Founder and CEO, Thrive Global; Nancy J. Kelley, President and CEO, Nancy J. Kelley & Associates and Former Founding Executive Director, New York Genome Center; Robert Klitzman, Director, Masters of Bioethics Program, Joseph Mailman School of Public Health, Columbia University; Tom Kottler, CEO, Co-Founder, HealthPrize Technologies; Steven Krein, Co-founder and CEO, StartUp Health; Andrew Kung, Chair and Professor, Department of Pediatrics, Memorial Sloan Kettering Cancer Center; Kristin Lemkau, Chief Marketing Officer, JPMorgan Chase; Christian Madsbjerg, Senior Partner, ReD Associates; John Mattison, Chief Medical Information Officer, Kaiser Permanente; Dan Munro, Author; Alexi Nazem, Co-founder and CEO, Nomad Health; Lynn O'Connor Vos, Chief Executive Officer, Grey Healthcare Group (ghg); Dean Ornish, President and Director, Preventive Medicine Research Institute; Meredith Salisbury, Editorial Director, Bioscribe; Mario Schlosser, Co-founder and CEO, Oscar; Brent Shafer, CEO, Philips North America; Seth Sternberg, Co-founder and CEO, Honor; Andrew Thompson, Co-founder and CEO, Proteus Digital Health, Inc.; and Steven Zatz, CEO, WebMD. Current agenda and additional information can be found at www.techonomy.com/health Techonomy NYC confirmed speakers include: Daniel Buchner, Senior PM - Head of Decentralized Identity at Microsoft, Microsoft; Beth Comstock, Vice Chair, GE; Meltem Demirors, Director, Development, Digital Currency Group; Diana Farrell, President and CEO, JPMorgan Chase Institute; Max Furmanov, Managing Director & Partner, Accenture; Andrea Glorioso, Counsellor, Digital Economy / Cyber, Delegation of the European Union to the USA; COL John Graham, Associate Dean for Research and Chief Scientist, United States Military Academy; Subramaniam Hariharan, VP Global Quality, Technology Innovation & Operational Excellence, Celestica; Jessi Hempel, Head of Editorial, Backchannel; Karin Klein, Head of Investing Activities, Bloomberg Beta; Fred Krupp, President, Environmental Defense Fund; Doreen Lorenzo, Co-founder, Vidlet Inc.; Director for the Center of Integrated Design, The University of Texas; Rachel Maguire, Research Director, Health Horizons Program, Institute for the Future; Gary Marcus, Professor, NYU; Founder, Geometric Intelligence (acquired by Uber); John Martin, Chairman and Chief Executive Officer, Turner; Miguel McKelvey, Co-founder and Chief Creative Officer, WeWork; Gregory McNeal, Co-Founder, AirMap; John Melkon, Center for the Study of Civil-Military Operations, United States Military Academy; Michael Monahan, Executive Vice President and Chief Operating Officer, Pitney Bowes; Eli Pariser, Co-founder and Co-CEO, Upworthy; Bre Pettis, Founder, Bre & Co.; Ernesto Quinteros, Chief Design Officer, Johnson & Johnson; Andrew Rasiej, Founder and Publisher, Personal Democracy Forum; Founder and CEO, Civic Hall; Slava Rubin, Chief Business Officer, Indiegogo; Julie Samuels, Executive Director, Tech:NYC; Jake Schwartz, Co-founder and CEO, General Assembly; Melanie Shapiro, Founder and CEO, Case; Oz Sultan, CEO, Sultan Interactive Group; Arun Sundararajan, Professor of Business, New York University; Author, "The Sharing Economy"; David Treat, Managing Director, Accenture; Bradley Tusk, Founder and CEO, Tusk Ventures; Michael J. Wolf, Co-founder and Managing Director, Activate, Inc.; and Tracy Young, CEO and Co-founder, PlanGrid. Current agenda and additional information can be found at www.techonomy.com/nyc Contacts: Techonomy Josh Kampel 617.233.7722 josh@techonomy.com Grayling Crystal Yang 415.593.1188 techonomy@grayling.com New York, NY, April 25, 2017 --( PR.com )-- GE’s Beth Comstock, Arianna Huffington of Thrive Global, and John Martin of Turner are among 60 speakers dissecting the role of tech on social and economic progress, and especially in health.Techonomy, a leading events and media company focused on helping organizations and executives prepare for the rapid pace of tech-enabled transformation, will hold two consecutive events, Techonomy Health & Techonomy NYC, in New York City on May 16th & 17th.“We love our home city in New York and we love helping leaders engage with ideas about tech-driven change, so we are especially proud to be doing that here for the second year in a row,” said David Kirkpatrick, CEO and Chief Techonomist and author of the bestselling book, The Facebook Effect: The Inside Story of the Company that is Connecting the World. "We're inviting techonomic thinkers to join us for either one or both of two days – Techonomy Health first, and then Techonomy NYC on May 17."Techonomy Health explores the vast potential tech holds to remake this $3 trillion U.S. industry. The program includes healthcare experts, technologists, policy makers and entrepreneurs for a high-energy discussion around topics including how AI and CRISPR will change the war on cancer, the future of consumer health information and media, the ethical and moral quandaries of enhancing the human genome, and what Trumpcare and Obamacare mean for health innovation. Speakers include Len Greer, President, Johnson & Johnson Health and Wellness; Meredith Guerriero, director for the healthcare industry at Facebook; Arianna Huffington, Founder and CEO, Thrive Global; John Mattison, Chief Medical Information Officer, Kaiser Permanente; celebrated author and holistic medicine expert Dean Ornish; Claudia González Romo, Executive Office of the Secretary General, UNICEF; Oscar CEO Mario Schlosser; Brent Shafer, CEO of Philips North America; and Steven Zatz, CEO of WebMD. (Full list below.)The following day, Techonomy NYC will be a New York-style version of Techonomy’s longstanding retreat in California, where last fall Mark Zuckerberg famously spoke about fake news. Techonomy NYC will ignite invigorating discourse around ongoing challenges relating to what a government led by Trump means for technology; the future of work in an on-demand gig economy; the digital and social fight against terrorism; and tough-to-answer questions about decision making power in an AI world, among many other topics. Speakers include Beth Comstock, Vice Chair of GE; Karin Klein, Head of Investing Activities at VC firm Bloomberg Beta; Environmental Defense Fund President Fred Krupp; Turner CEO John Martin; Miguel McKelvey, Co-founder and Chief Creative Officer of WeWork; Eli Pariser, Co-founder and Co-CEO of Upworthy; and General Assembly CEO Jake Schwartz. (Full list below.)Techonomy's partners for the conferences include Accenture, Celestica, Cognizant, Johnson & Johnson, Paypal, Philips, Pitney-Bowes, and Turner Broadcasting.Techonomy Health confirmed speakers include:Yonatan Adiri, Founder and CEO, Healthy.io and Founder, DisruptionLabs; Agnes Binagwaho Vice Chancellor, University of Global Health Equity; Jef Boeke, Director of the Institute for Systems Genetics, NYU Langone Medical Center; Walter De Brouwer, Founder and CEO, doc.ai; Brian Donley, Chief of Staff, Cleveland Clinic; David Ewing Duncan, Co-Founder, Curator and CEO, Arc Fusion; Esther Dyson, Chairman, EDventure Holdings; Katelyn Gleason, CEO & Cofounder, Eligible; Claudia González Romo, Executive Office of the Secretary General, UNICEF; Len Greer, President, Johnson & Johnson Health and Wellness Solutions; Meredith Guerriero, director for the healthcare industry at Facebook Ron Gutman, Founder and CEO, HealthTap; Jill Hagenkord, Chief Medical Officer, Color Genomics; Arianna Huffington, Founder and CEO, Thrive Global; Nancy J. Kelley, President and CEO, Nancy J. Kelley & Associates and Former Founding Executive Director, New York Genome Center; Robert Klitzman, Director, Masters of Bioethics Program, Joseph Mailman School of Public Health, Columbia University; Tom Kottler, CEO, Co-Founder, HealthPrize Technologies; Steven Krein, Co-founder and CEO, StartUp Health; Andrew Kung, Chair and Professor, Department of Pediatrics, Memorial Sloan Kettering Cancer Center; Kristin Lemkau, Chief Marketing Officer, JPMorgan Chase; Christian Madsbjerg, Senior Partner, ReD Associates; John Mattison, Chief Medical Information Officer, Kaiser Permanente; Dan Munro, Author; Alexi Nazem, Co-founder and CEO, Nomad Health; Lynn O'Connor Vos, Chief Executive Officer, Grey Healthcare Group (ghg); Dean Ornish, President and Director, Preventive Medicine Research Institute; Meredith Salisbury, Editorial Director, Bioscribe; Mario Schlosser, Co-founder and CEO, Oscar; Brent Shafer, CEO, Philips North America; Seth Sternberg, Co-founder and CEO, Honor; Andrew Thompson, Co-founder and CEO, Proteus Digital Health, Inc.; and Steven Zatz, CEO, WebMD.Current agenda and additional information can be found at www.techonomy.com/healthTechonomy NYC confirmed speakers include:Daniel Buchner, Senior PM - Head of Decentralized Identity at Microsoft, Microsoft; Beth Comstock, Vice Chair, GE; Meltem Demirors, Director, Development, Digital Currency Group; Diana Farrell, President and CEO, JPMorgan Chase Institute; Max Furmanov, Managing Director & Partner, Accenture; Andrea Glorioso, Counsellor, Digital Economy / Cyber, Delegation of the European Union to the USA; COL John Graham, Associate Dean for Research and Chief Scientist, United States Military Academy; Subramaniam Hariharan, VP Global Quality, Technology Innovation & Operational Excellence, Celestica; Jessi Hempel, Head of Editorial, Backchannel; Karin Klein, Head of Investing Activities, Bloomberg Beta; Fred Krupp, President, Environmental Defense Fund; Doreen Lorenzo, Co-founder, Vidlet Inc.; Director for the Center of Integrated Design, The University of Texas; Rachel Maguire, Research Director, Health Horizons Program, Institute for the Future; Gary Marcus, Professor, NYU; Founder, Geometric Intelligence (acquired by Uber); John Martin, Chairman and Chief Executive Officer, Turner; Miguel McKelvey, Co-founder and Chief Creative Officer, WeWork; Gregory McNeal, Co-Founder, AirMap; John Melkon, Center for the Study of Civil-Military Operations, United States Military Academy; Michael Monahan, Executive Vice President and Chief Operating Officer, Pitney Bowes; Eli Pariser, Co-founder and Co-CEO, Upworthy; Bre Pettis, Founder, Bre & Co.; Ernesto Quinteros, Chief Design Officer, Johnson & Johnson; Andrew Rasiej, Founder and Publisher, Personal Democracy Forum; Founder and CEO, Civic Hall; Slava Rubin, Chief Business Officer, Indiegogo; Julie Samuels, Executive Director, Tech:NYC; Jake Schwartz, Co-founder and CEO, General Assembly; Melanie Shapiro, Founder and CEO, Case; Oz Sultan, CEO, Sultan Interactive Group; Arun Sundararajan, Professor of Business, New York University; Author, "The Sharing Economy"; David Treat, Managing Director, Accenture; Bradley Tusk, Founder and CEO, Tusk Ventures; Michael J. Wolf, Co-founder and Managing Director, Activate, Inc.; and Tracy Young, CEO and Co-founder, PlanGrid.Current agenda and additional information can be found at www.techonomy.com/nycContacts:TechonomyJosh Kampel617.233.7722josh@techonomy.comGraylingCrystal Yang415.593.1188techonomy@grayling.com


April 24, 2017 -- In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center with an interdisciplinary team of colleagues at MD Anderson Cancer Center, University of Michigan, Memorial Sloan Kettering Cancer Center, and other institutions in the U.S. and Canada, analyzed which integrative treatments are most effective and safe for patients with breast cancer. This systematic review adds to the growing literature on integrative therapies for patients with breast cancer and other cancer populations. The latest results are published online and in print in CA: A Cancer Journal for Clinicians, a publication of the American Cancer Society. The researchers evaluated more than 80 different therapies and developed grades of evidence. Based on those findings, the Society for Integrative Oncology makes the following recommendations: "Studies show that up to 80 percent of people with a history of cancer use one or more complementary and integrative therapies, but until recently, evidence supporting the use of many of these therapies had been limited," said Heather Greenlee, ND, PhD, assistant professor of Epidemiology at Columbia University's Mailman School of Public Health, and past president of SIO. "Our goal is to provide clinicians and patients with practical information and tools to make informed decisions on whether and how to use a specific integrative therapy for a specific clinical application during and after breast cancer treatment," Greenlee continues. In their systematic evaluation of peer-reviewed randomized clinical trials, the researchers assigned letter grades to therapies based on the strength of evidence. A letter grade of "A" indicates that a specific therapy is recommended for a particular clinical indication, and there is high certainty of substantial benefit for the patient. Meditation had the strongest evidence supporting its use, and is recommended for reducing anxiety, treating symptoms of depression, and improving quality of life, based on results from five trials. Music therapy, yoga, and massage received a B grade for the same symptoms, as well as for providing benefits to breast cancer patients. Yoga received a B grade for improving quality of life based on two recent trials. Yoga and hypnosis received a C for fatigue. "The routine use of yoga, meditation, relaxation techniques, and passive music therapy to address common mental health concerns among patients with breast cancer is supported by high levels of evidence," said Debu Tripathy, MD, chair of Breast Oncology at The University of Texas MD Anderson Cancer Center, and a past president of SIO. "Given the indication of benefit coupled with the relatively low level of risk, , these therapies can be offered as a routine part of patient care, especially when symptoms are not well controlled." Acupressure and acupuncture received a B grade as an addition to drugs used for reducing chemotherapy-induced nausea and vomiting. In general, there was a lack of strong evidence supporting the use of ingested dietary supplements and botanical natural products as part of supportive cancer care and to manage treatment-related side effects. "Clinicians and patients need to be cautious about using therapies that received a grade of C or D and fully understand the potential risks of not using a conventional therapy that may effectively treat cancer or help manage side effects associated with cancer treatment," warned Lynda Balneaves, RN, PhD, associate professor, College of Nursing, Rady Faculty of Health Sciences, Winnipeg, Canada, and president-elect of SIO. "Patients are using many forms of integrative therapies with little or no supporting evidence and that remain understudied," noted Dr. Greenlee. "This paper serves as a call for further research to support patients and healthcare providers in making more informed decisions that achieve meaningful clinical results and avoid harm." Additional co-authors: Melissa J. DuPont-Reyes, Department of Epidemiology, Mailman School of Public Health, Columbia University; Linda Carlson, Department of Oncology, University of Calgary, Calgary, AB, Canada; Misha Cohen, American College of Traditional Chinese Medicine at California Institute of Integral Studies, and Chicken Soup Chinese Medicine, San Francisco; Gary Deng, Integrative Oncology, Memorial Sloan Kettering Cancer Center, New York City; Jillian A. Johnson, Department of Biobehavioral Health, The Pennsylvania State University, University Park; Matthew Mumber, Department of Radiation Oncology,Harbin Clinic, Rome, GA; Dugald Seely, Ottawa Integrative Cancer Center, Ottawa, ON, and Canadian College of Naturopathic Medicine, Toronto, ON; Suzanna M. Zick, Department of Family Medicine, University of Michigan Health System, and Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor; and Lindsay M. Boyce, Memorial Sloan Kettering Library, Memorial Sloan Kettering Cancer Center, New York City. Founded in 1922, Columbia University's Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master's and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit http://www. .


Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable. In recent years, the FDA has approved six drugs for men with metastatic disease, all of which can increase survival. In a study published in Urology®, researchers demonstrate for the first time that an aggressive combination of systemic therapy (drug treatment) with local therapy (surgery and radiation) directed at both the primary tumor and metastasis can eliminate all detectable disease in selected patients with metastatic prostate cancer. While the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months. The results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate). Such results could not have been achieved with any single therapy alone. According to lead investigator Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, "The sequential use of the three different modalities helped illustrate the role and importance of each in achieving the undetectable PSA with normal testosterone level end point, which represents a 'no-evidence of disease' status." Longer follow-up is needed to determine whether these patients were in fact cured. Twenty men with metastatic prostate cancer, five with extra-pelvic lymph nodal disease and 15 with bone with or without nodal disease, were treated with androgen deprivation therapy (ADT), radical surgery that included a retroperitoneal lymph node dissection as needed, and radiation therapy to visible metastatic lesions in bone. ADT was stopped after a minimum of six months if an undetectable PSA was achieved after combined modality therapy. Other patients were treated continuously. The combined treatment regimen including surgery was well tolerated. Matthew J. O'Shaughnessy, MD, PhD, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, commented "While the role of local therapy in metastatic prostate cancer is still under investigation, aggressive resection of visible disease performed by experienced surgeons was critical to the outcome." Of the five patients with extra-pelvic lymph node involvement, four achieved an undetectable PSA after ADT and surgery, while the fifth needed radiation to reach this milestone. However, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used. Ultimately, four (27%) achieved the proposed end point, a PSA of 150 ng/dL at 20 months after the start of ADT, which remained undetectable in two patients for 27 and 46 months, respectively. Commenting on the study, Oliver Sartor, MD, Cancer Research, Department of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA, stated, "The end point deserves special mention, as the end point of undetectable PSA after testosterone recovery has been previously discussed but rarely studied. The authors proposed that this end point may serve as a first step toward establishing a curative paradigm. Many in the field agree, but note that the longevity of effect is essential to prove the point of curability. Regardless, the movement toward a curative paradigm is much needed and the investigators are to be congratulated for setting forth a paradigm that can be used to assess the possibility of cure in a reasonable period of time." "A multimodal treatment strategy for patients who present with disease that is beyond the limits of curability by any single modality enables the evaluation of new approaches in order to prioritize large-scale testing in early stages of advanced disease. The end point also shifts the paradigm from palliation to cure," remarked Dr. Scher. It is expected that an upcoming Phase 2 trial will further test this endpoint and combined modality approach.

Loading Memorial Sloan Kettering Cancer Center collaborators
Loading Memorial Sloan Kettering Cancer Center collaborators